$NKTX

Nkarta, Inc.

Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer cell therapies. Its lead product candidate, NKX019, is designed to target CD19-positive B cells and is being studied for autoimmune diseases including lupus nephritis, primary membranous nephropathy, scleroderma, myositis, and ANCA-associated vasculitis. Nkarta also studies NKX019 in investigator-sponsored trials for systemic lupus erythematosus and myasthenia gravis. The company’s earlier oncology studies of NKX019 and NKX101, a candidate targeting cells that display NKG2D ligands, closed enrollment in 2023 and have been deprioritized. Nkarta’s platform uses mature NK cells from healthy donors, which it engineers, expands, and cryopreserves for off-the-shelf use. Its engineered cells combine a targeting receptor with signaling and persistence-enhancing components. Nkarta manufactures clinical supply at one of its two cGMP facilities in South San Francisco, California, and is headquartered in South San Francisco, California.

AlphAI earnings readThird Quarter 2026 · NOV 5Nkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
1

No SEC Form 4 filings for $NKTX in the last 30 days.

See all $NKTX insider activity →

NKTX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning NKTX (Nkarta, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent NKTX coverage spans financial news and earnings.

What's driving NKTX

AlphAI scores every news story that mentions NKTX with an AI model for sentiment and relevance, and aggregates insider trades from Nkarta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NKTX

Score
$NKTXMedAI 9/10Clinical / regulatory· topline data

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence • In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by

$NKTXMedAI 9/10

Nkarta reports early trial data for autoimmune cell therapy

Nkarta Inc. (NKTX) presented early trial data for NKX019, an experimental cell therapy for autoimmune diseases. In trials with 40 patients, 83% of myositis patients and 86% of systemic sclerosis patients showed significant responses. No serious adverse events were reported. Nkarta plans to evaluate higher doses and discuss potential registration pathways with the FDA.

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer

Nkarta 3Q 2026: EPS ($0.45) — 10-Q Summary

Nkarta reported a wider net loss in 3Q 2026, with a loss of $33.33M compared to $21.72M a year earlier, due to increased R&D spending and lower interest income. R&D expenses rose to $29.5M, driven by higher program costs and clinical spending for NKX019. The company had $216.0M in cash and investments as of September 30, 2026, and is conducting clinical trials for NKX019 in various conditions.

$NKTXMedEarnings

Nkarta Reports Third Quarter 2026 Financial Results

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update • Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 • Cash balance of $216.0 mi

Cash and equivalents are expected to fund Nkarta’s plan into 2029. Initial trial data are scheduled for November.

Nkarta, Inc. (NKTX) reported $216.0M in cash and equivalents as of Q3 2026, expecting to fund operations into 2029. The company will present initial clinical data for NKX019 in myositis and systemic sclerosis at ACR Convergence 2026. NKX019 is an engineered NK cell therapy for autoimmune diseases, with trials ongoing in multiple indications. Nkarta reported a net loss of $33.3M for Q3 2026, with R&D and G&A expenses of $29.5M and $6.3M, respectively.

H.C. Wainwright initiates Nkarta stock coverage with buy rating

H.C. Wainwright initiated coverage on Nkarta Inc. (NASDAQ: NKTX) with a buy rating and a $12.00 price target, citing its differentiated CAR-NK program. The stock trades at $1.56, near its 52-week low, with a market cap of $111.73 million. Analysts highlight NKX019's potential in autoimmune diseases and upcoming data presentations. Stifel reiterated a buy rating but lowered its target to $10.00, while H.C. Wainwright reduced its target to $14.00.

Related tickers